Insulet (PODD) EPS (Weighted Average and Diluted) (2016 - 2026)

Insulet has reported EPS (Weighted Average and Diluted) for 11 years, with the latest figure at $1.3 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 160.0% year-over-year to $1.3; the trailing twelve-month figure through Mar 2026 stood at $4.29 (down 22.7% YoY), and the FY2025 full-year result was $3.48, down 39.79% from the prior year.
• EPS (Weighted Average and Diluted) for Q1 2026 stood at $1.3, down from $1.43 in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was $2.59 in Q2 2024, with the low at -$0.5 in Q2 2022.
• Historically, EPS (Weighted Average and Diluted) has averaged $0.8 across 5 years, with a median of $0.73 in 2024.
• Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) tumbled 144.44% — and 2023, when it soared 1025.0%.
• Insulet's EPS (Weighted Average and Diluted) stood at $0.25 in 2022, then soared by 488.0% to $1.47 in 2023, then decreased by 6.12% to $1.38 in 2024, then climbed by 3.62% to $1.43 in 2025, then slipped by 9.09% to $1.3 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $1.3 (Q1 2026), $1.43 (Q4 2025), and $1.24 (Q3 2025), per Business Quant data.